GelMEDIX Completes $13M Seed Financing
GelMEDIX, a biopharmaceutical company focused on regenerative medicine for ocular diseases, announced the completion of a $13 million seed financing round. The company is developing novel therapies delivered via a proprietary hydrogel platform. The funding highlights continued investor interest in early-stage regenerative medicine ventures.
- The seed round was led by Safar Partners, a firm that primarily invests in technology companies originating from MIT and Harvard. Other investors included HTL Biotechnology, Beacon Angels, TiE Boston Angels, and Boston Harbor Angels. - Proceeds are earmarked for advancing GelMEDIX's lead program, GMX-101, a cell therapy aimed at treating late-stage Geographic Atrophy (GA), a progressive form of dry age-related macular degeneration that leads to irreversible vision loss. - In conjunction with the financing, GelMEDIX entered into a strategic partnership with an undisclosed global pharmaceutical company. The partner will utilize GelMEDIX's hydrogel scaffold technology with its own stem cell lines to develop new therapies. - The company’s core technology is an injectable hydrogel made of chemically modified natural polymers that is injected as a liquid and then activated by light to form a solid, biodegradable scaffold at the target site. This scaffold is designed to mimic the properties of natural human tissue, supporting cell adhesion and growth. - As part of the financing deal, two new members were appointed to the GelMEDIX Board of Directors: Michael J. Cima, PhD, a Professor of Engineering at the Massachusetts Institute of Technology, and Parinaz Motamedy, a Partner at the lead investment firm, Safar Partners. - GelMEDIX was co-founded by Reza Dana, MD, a Professor of Ophthalmology at Harvard Medical School, and Nasim Annabi, PhD, an Associate Professor of Chemical Engineering at UCLA. - The global market for regenerative medicine was valued at over $43 billion in 2024 and is projected to grow to more than $157 billion by 2032. Specifically, the market for cell-based ophthalmic therapies is expected to reach $3.14 billion by 2029.
